Levetiracetam extended release - Sun Pharma Advanced Research Company

Drug Profile

Levetiracetam extended release - Sun Pharma Advanced Research Company

Alternative Names: Elepsia XR

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epilepsy

Most Recent Events

  • 18 Jul 2016 Levetiracetam extended release licensed to Sun Pharmaceutical Industries in USA
  • 15 Mar 2016 Biomarkers information updated
  • 01 Sep 2015 Sun Pharma Advanced Research Company receives complete response letter from the FDA for levetiracetam in Epilepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top